All GLP-1 medications from licensed 503A compounding pharmacies Browse Products
Telehealth Provider — FDA safety data from public records
Telehealth company centered on compounded GLP-1 weight loss access through online consultations and subscription-style recurring billing.
Website: henrymeds.com
Data last verified: 2026-04-25
Entity Type
Telehealth Provider
FDA Registration
Not shown
Warning Letters
0
Recalls
0
States Licensed
48
Compounding Status
unknown
Henry Meds is best understood as a telehealth front end rather than a manufacturer. Patients usually encounter the brand through online intake, clinician review, subscription billing, fulfillment coordination, and follow-up support, while the medication supply chain sits behind the scenes with partner pharmacies or outsourcing facilities.
Henry Meds reports coverage across 48 states, which suggests a relatively broad operating footprint rather than a niche single-state presence. For SEO and user trust, that means the important question is not just "is Henry Meds legitimate" but "who is prescribing, who is compounding or dispensing, and what claims is the company making about those medications?"
Telehealth companies can scale quickly because marketing, acquisition, and patient communications are centralized. The tradeoff is that a polished consumer brand can sometimes hide weak transparency around pharmacy sourcing, state licensure details, refill logic, escalation paths, and how the company handles adverse events or billing disputes.
Henry Meds occupies the value-focused, high-volume segment of the telehealth GLP-1 market. It is commonly researched by patients looking for compounded medication access at a lower advertised monthly cost than premium or brand-name-first platforms.
The brand is built around straightforward online prescribing and recurring medication access rather than deep behavior-change programming. That keeps the model simple for users, but it also means the safety conversation tends to focus on sourcing transparency, support responsiveness, and billing clarity.
Henry Meds is best evaluated by looking at how clearly it explains who is compounding, how fulfillment works, and whether operational integration creates better oversight or simply concentrates more regulatory exposure inside one commercial system.
With lower-cost compounded sellers, the recurring risk is that patients optimize for price before they verify service quality, pharmacy details, or escalation paths. Henry Meds should therefore be judged not only on affordability but on transparency and post-purchase support.
Henry Meds is usually compared against other lower-cost compounded GLP-1 telehealth providers rather than premium obesity-medicine programs.
Its appeal is convenience and price simplicity, but that makes source transparency and service quality more important, not less.
Patients should verify how the company handles pharmacy disclosure, cancellations, dose changes, and support when treatment problems arise.
No FDA warning letters are currently shown in this profile.
No recall events are currently shown in the FDA enforcement data surfaced here.
No direct FDA establishment registration record is displayed on this page.
The page shows an operating footprint of 48 states.
Henry Meds does not appear in this profile as a directly FDA-registered drug establishment. That is common for telehealth platforms because they usually operate as prescriber and logistics layers while medications are sourced through partner pharmacies or outsourcing facilities.
We did not find FDA warning letters for Henry Meds in this profile. That is better than the alternative, but it is not a blanket endorsement. A clean warning-letter record only tells you that this page is not currently surfacing a published FDA warning letter tied to the entity.
No recall events are shown for Henry Meds here. For consumers, that lowers one category of concern, but it still does not replace verification of sourcing, labeling, temperature handling, and pharmacy quality controls.
This profile does not currently show a meaningful adverse-event dataset for Henry Meds. In practice, that usually means readers should lean more heavily on registration, recalls, warning letters, and pharmacy-partner transparency when evaluating risk.
No direct FDA establishment registration record is shown in this profile for Henry Meds. For telehealth companies, that is often expected because the brand may coordinate care while external pharmacies or outsourcing facilities handle compounding or dispensing. Readers should verify the underlying pharmacy partner rather than relying on the consumer brand alone.
No FDA warning letters are currently shown for Henry Meds in this profile. That is helpful context, but users should still verify current marketing claims, pharmacy sourcing, and how the company describes compounded medications.
No recalls are currently displayed for Henry Meds in the openFDA enforcement data surfaced on this page. That lowers one obvious risk signal, but it should not be treated as proof that all products, batches, or fulfillment practices are problem-free.
Source: openFDA Drug Enforcement API
This profile does not currently show a meaningful adverse-event summary for Henry Meds. When that dataset is absent, readers should lean more on the documented public record around registration, recalls, warning letters, and pharmacy-partner transparency.
Source: FDA Adverse Event Reporting System (FAERS). Adverse event reports do not establish causation.
Which pharmacy or outsourcing facility is actually filling Henry Meds prescriptions, and can you name it before checkout?
What does Henry Meds tell patients about compounded versus FDA-approved products, and does that language avoid implying equivalence or approval where it does not exist?
How does Henry Meds handle dose escalations, refill delays, refunds, cancellations, and temperature-sensitive shipping problems?
If a patient has a side effect or receives a product-quality concern, what is the human escalation path and how quickly does Henry Meds respond?
Can Henry Meds provide lot-level documentation, pharmacy details, and a clear explanation of what safety checks happen before medication is dispensed?
These related profiles are useful for searchers comparing Henry Meds against adjacent providers or pharmacies. Reading similar pages side by side usually reveals whether a concern is unique to one company or common across this category.
This profile organizes public-source safety signals for Henry Meds, including FDA registration status, warning letters, recalls, and any adverse event summary data available in the dataset.
A company can appear relatively clean here and still deserve more diligence, because absence of a warning letter or recall is not the same as proof of quality.
For telehealth provider pages especially, readers should distinguish between the consumer-facing brand and the pharmacy or facility that actually handles medication production or dispensing.
Use these links to validate the key claims in this profile and to separate the consumer-facing brand story from the underlying regulatory record.
Henry Meds official website
Primary company website used to verify platform scope and recurring-program positioning.
Henry Meds programs and legal page
Supports the compounded-pharmacy fulfillment and program-structure claims referenced in this profile.
FormBlends partners with licensed 503A compounding pharmacies. Every compound is third-party tested with certificates of analysis.
Learn MoreDisclaimer: This page aggregates publicly available data from the FDA, state pharmacy boards, and other government sources. It is provided for informational purposes only and does not constitute medical or legal advice. FDA registration does not imply FDA approval or endorsement. The absence of warning letters or recalls does not guarantee safety or quality. Always consult your healthcare provider before making decisions about medications. Data may not reflect the most current status. Last updated: 2026-04-25.
503A vs 503B pharmacies
Understanding the FDA oversight difference.
How to read a Certificate of Analysis
What every CoA should include and red flags to watch for.
What FDA registration actually means
Registration vs approval: the distinction most people miss.
Choosing a compounding pharmacy
What to verify before you fill your first prescription.
Get notified when the FDA issues warning letters, recalls, or regulatory updates affecting GLP-1 medications and compounding pharmacies.
Free. No spam. Unsubscribe anytime.
We do not currently have FDA registration data for Henry Meds. This may mean the company operates under a different entity name or is regulated at the state level.
We have not found any FDA warning letters issued to Henry Meds in our records. This page is updated regularly as new FDA data becomes available.
We have not found any recalls associated with Henry Meds in the openFDA enforcement database.
Henry Meds is categorized in this profile as a telehealth provider. That distinction matters because a telehealth brand, a 503A pharmacy, and a 503B outsourcing facility operate under different regulatory expectations.
No. A clean profile means we are not currently surfacing certain FDA signals like warning letters or recalls for Henry Meds. It does not guarantee product quality, customer-service quality, or future regulatory compliance.
Patients should verify who is prescribing, which pharmacy or outsourcing facility is actually fulfilling the medication, what the company says about compounded versus FDA-approved products, and how billing, cancellations, and side-effect escalation are handled.